Adenovirus Expressing Mutant p27kip1 Enhanced Apoptosis against Cholangiocarcinoma than Adenovirus-p27kip1 Wild Type

Hepato-Gastroenterology

Volumn 51, Issue 55, 2004, Pages 68-75

  Sasaki, Tsuyoshi ^a   Katayose, Yu ^a   Suzuki, Masanori ^a   Yamamoto, Kuniharu ^a   Shiraso, Satoru ^a   Mizuma, Masamichi ^a   Unno, Michiaki ^a   Takeuchi, Heigo ^a   Lee, Choon Taek ^b   Matsuno, Seiki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Seoul National University   (South Korea)

Author keywords

Adenovirus; Apoptosis; Cholangiocarcinoma; Mutant; p27kip1

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR; MUTANT PROTEIN; PROTEASOME INHIBITOR; PROTEIN KINASE; PROTEIN P27; UBIQUITIN;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFECTION; MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION; VIRUS EXPRESSION; VIRUS RECOMBINANT; WILD TYPE;

ADENOVIRIDAE; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL CYCLE PROTEINS; CHOLANGIOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LAC OPERON; PRECIPITIN TESTS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 10744229584     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Suzuki M, Takahashi T, Ouchi K, Matsuno S: The development and extension of hepatohilar bile duct carcinoma. A three-dimensional tumor mapping in the intrahepatic biliary tree visualized with the aid of a graphics computer system. Cancer 1989; 64:658-666.
2. Suzuki M, Takahashi T, Ouchi K, Matsuno S: Perineural tumor invasion and its relation with the lymphogenous spread in human and experimental carcinoma of bile duct. A computer-aided 3-Dreconstruction study. Tohoku J Exp Med 1994; 172:17-28.
3. Katayose Y, Kudo Y, Suzuki M, Shinoda M, Saijo S, Sakurai N, Saeki H, Fukuhara K, Imai K, Matsuno S: MUC1-specific targeting immunotherapy with bispecific antibody: inhibition of xenografted human bile duct carcinoma growth. Cancer Res 1996; 15:4205-4212.
4. Takemura S, Kudo T, Asano R, Suzuki M, Tsumoto K, Sakurai N, Katayose Y, Kodama H, Yoshida H, Ebara S, Saeki H, Imai K, Matsuno S, Kumagai I: A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol Im 2002; 51:33-44.
5. Petmitr S, Pinlaor S, Thousungnoen A, Karalak A, Migasena P: K-ras oncogene and a p53 gene mutation in cholangiocarcinoma from Thai patient. SE Asian J Trop Med Public Health 1998; 29:71-75.
6. Kang YK, Kim WH, Lee HW, Lee HK, Kim YI: Mutation of p53 gene and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999; 79:477-483.
7. Sherr CJ: Cancer cell cycles. Science 1996; 274:1672-1677.
8. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.
9. Steeg PS, Abrams JS: Cancer prognostics: past, present and p27 [news; comment]. Nat Med 1997; 3:152-154.
10. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients [see comments]. Nat Med 1997; 3:222-225.
11. Esposito V, Baldi A, Luca AD, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the Cyclin-dependent Kinase Inhibitor p27 in Non-Small Cell Lung Cancer. Cancer Res 1997; 57:3381-3385.
12. kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 2000; 6:4816-4822.
13. kip1 combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinoma. Int J Oncol 2001; 18:17-23.
14. Toyoshima T, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78:67-74.
15. kip1. Cell 1996; 85:721-732.
16. kip1 induced cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997; 14:2283-2289.
17. Katayose D, Wersto R, Cowan KH, Seth P: Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Diff 1995; 6:1207-1212.
18. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P: Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997; 57:5441-5445.
19. kip1: a strategy for breast cancer gene therapy. J Natl Cancer Inst 1998; 90:1836-1838.
20. kip1 by two mechanism, Ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999; 274:13886-13893.
21. kip1. Genes Dev 1997; 11:1464-1478.
22. kip1. EMBO J 1997; 16:5334-5344.
23. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13:1181-1189.
24. Kyung-Ho P, Ja YS, Tae-You K, Chul-Gyu Y, Young WK, Sung KH, Young-Soo S, Choon-Taek L: An adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res 2001; 61:6163-6169.
25. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S: Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 1995; 177:61-71.
26. INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 1998; 16:265-272.
27. kip1. Biochem Biophys Res Commun 1998; 253:671-677.
28. Fiorentino M, Altimari A, Errico A, Cukor B, Barozzi C, Loda M, Griginoni WF: Acquired expression of p27 is sa favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000; 6:3966-3972.
29. kip1 expression in normal epithelia, precancerous lesions and carcinomas of the gall-bladder, association with cancer progression and prognosis. Hepatology 2000; 31:1068-1072.
30. Michelangelo F, Annalisa A, Antonia D, Elena G, Pasquale C, Michele M, Walter FG: Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. Clin Cancer Res 2001; 7:3994-3999.
31. 2/M DNA damage checkpoint. Genes Dev 2000; 14:1448-1459.
32. Enoch T, Nurse P: Mutation of fission yeast cell cycle control genes abolishes dependence of mitosis on DNA replication. Cell 1990; 60:665-673.
33. INK4B/MTS2 genes inbiliary tract cancers. Cancer Res 1995; 55:2756-2760.
34. kip1 induces apoptosis against cholangiocarcinoma cells by triggering Fas ligand on the cell surface. Hepatogastroenterology 2003; 50:1847-1853.
35. Ekholm SV, Reed SI: Regulation of G1 cyclin-dependent kinase in the mammalian cell cycle. Curr Opin Cell Biol 2000; 12:676-684.
36. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Sal GD, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-685.
37. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM: Interleukin-2-mediated elimination of the p27kip cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570-573.